RARE Stock Summary and Trading Ideas (Ultragenyx Pharmaceutical | NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical trades on the NASDAQ stock market under the symbol RARE.

As of March 5, 2025, RARE stock price declined to $40.87 with 778,901 million shares trading.

RARE has a beta of 0.92, meaning it tends to be less sensitive to market movements. RARE has a correlation of 0.09 to the broad based SPY ETF.

RARE has a market cap of $3.78 billion. This is considered a Mid Cap stock.

Last quarter Ultragenyx Pharmaceutical reported $165 million in Revenue and -$1.39 earnings per share. This beat revenue expectation by $6 million and missed earnings estimates by -$.12.

In the last 3 years, RARE traded as high as $85.53 and as low as $31.52.

The top ETF exchange traded funds that RARE belongs to (by Net Assets): VTI, VB, VXF, VBK, XBI.

RARE has underperformed the market in the last year with a price return of -23.3% while the SPY ETF gained +15.2%. RARE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.2% and -6.3%, respectively, while the SPY returned -3.7% and -4.6%, respectively.

RARE support price is $40.03 and resistance is $42.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RARE shares will trade within this expected range on the day.